Bronchiectasis Clinical Trials

Bronchiectasis and NTM Research Registry/COPD Foundation

The Bronchiectasis Research Registry is a consolidated database of non-cystic fibrosis (non-CF) Bronchiectasis and Nontuberculous  Mycobacteria (NTM) patients from multiple clinical institutions. The goal of the Bronchiectasis Research Registry is to support collaborative research and assist in the planning of multi-center clinical trials for the treatment of NTM and non-CF Bronchiectasis, a progressive, non-curable disease of the lungs, which afflicts thousands of patients. The Registry will also be used to provide better insight into the study of the different types of Bronchiectasis, as well as the pathophysiology of the disorder. In 2012, in collaboration with NTM Info and Research, Inc (NTMir) and the consortium members, the COPD Foundation expanded the Bronchiectasis Research Registry to enroll patients with "non tuberculous mycobacteria (NTM) only."


MAC 2 x 3

  • Patient Centered Outcomes Research Institute (PCORI)
  • Multicenter randomized pragmatic clinical trial comparing two-versus three antibiotic therapy in patients with¬† pulmonary Mycobacterium avium complex disease.
  • Principal Investigator Kevin Winthrop, MD; Oregon Health and Science University
  • Determine whether 2-drug therapy is non-inferior to 3-drug therapy against pulmonary MAC and whether 2-drug therapy is better tolerated than 3-drug therapy.
  • Determine whether 2-drug therapy is better than 3-drug therapy with regards to changes in health-related quality of life, rates of specified adverse events, and whether 2-drug therapy is similar to 3-drug therapy with regards to the development of macrolide resistance.

The Aspen Trial

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Brensocatib Administered once Daily for 52 weeks in Subjects with Non-Cystic Fibtosis Bronchiectasis


Insmed Incorporated

To assess effect on reducing exacerbations in patients with bronchiectasis who have had 2 or more pulmonary exacerbations in the past year.


LIBERTY -ABPA AIRED

ABPA Investigating Respiratory Exacerbations with Dupilumab


Regeneron Pharmaceuticals, Inc.

A Randomized Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis

Physicians:

  • Angela DiMango, MD
  • Emily DiMango, MD
  • Claire Keating, MD
  • Byron Thomashaw, MD